2026年3月5日,テバのインサイダーが1300万ドル以上の株を売却した.これは,同社が強い利益を報告し,2026年の予測を上げたためであった. On March 5, 2026, Teva insiders sold over $1.3 million in stock as the company reported strong earnings and raised its 2026 forecast.

2026年3月5日,テバ製薬産業の複数のインサイダーが,執行副社長,別のインサイダー,エリック・ヒューズを含む株を売却し,集団的に彼らの株を大幅に削減しました. On March 5, 2026, multiple insiders at Teva Pharmaceutical Industries sold shares, including an executive vice president, another insider, and Eric Hughes, collectively reducing their stakes by significant percentages. 証券取引委員会に提出された取引は,総額130万ドルを超える. The transactions, disclosed in SEC filings, totaled over $1.3 million. Tevaの株は3月9日に3.44ドル上昇し,高額なQ4収益と2026年度の増収の予測に続き,取引量が高騰した. Teva’s stock rose to $31.44 on March 9, with elevated trading volume, following strong Q4 earnings and an upgraded 2026 earnings forecast. 会社は0.96ドル/年当たりの利益を報告し,予想を上回り,売上高は前年比11.4%増加した. The company reported $0.96 EPS, exceeding estimates, and revenue up 11.4% year-over-year. 分析者は"適度な買い"のコンセンサスを維持し,目標値は37.67ドルである. Analysts maintain a “Moderate Buy” consensus with a target of $37.67.